The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

F. Barkhof; R. Jong; N. Sfikas; A. de Vera; G. Francis; J. Cohen

doi:10.1177/1352458514532317

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

F. Barkhof
, R. Jong
, N. Sfikas
, A. de Vera
, G. Francis
, J. Cohen

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1704-1713
Journal	Multiple Sclerosis
Volume	20
Issue number	13
DOIs	https://doi.org/10.1177/1352458514532317
Publication status	Published - 2014

Access to Document

10.1177/1352458514532317

Cite this

Barkhof, F., Jong, R., Sfikas, N., de Vera, A., Francis, G., & Cohen, J. (2014). The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis, 20(13), 1704-1713. https://doi.org/10.1177/1352458514532317

Barkhof, F. ; Jong, R. ; Sfikas, N. et al. / The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. In: Multiple Sclerosis. 2014 ; Vol. 20, No. 13. pp. 1704-1713.

@article{ac9cda571d1b445d9b6f9b99ee936258,

title = "The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis",

author = "F. Barkhof and R. Jong and N. Sfikas and \{de Vera\}, A. and G. Francis and J. Cohen",

year = "2014",

doi = "10.1177/1352458514532317",

language = "Undefined/Unknown",

volume = "20",

pages = "1704--1713",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "13",

}

Barkhof, F, Jong, R, Sfikas, N, de Vera, A, Francis, G & Cohen, J 2014, 'The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis', Multiple Sclerosis, vol. 20, no. 13, pp. 1704-1713. https://doi.org/10.1177/1352458514532317

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. / Barkhof, F.; Jong, R.; Sfikas, N. et al.
In: Multiple Sclerosis, Vol. 20, No. 13, 2014, p. 1704-1713.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

AU - Barkhof, F.

AU - Jong, R.

AU - Sfikas, N.

AU - de Vera, A.

AU - Francis, G.

AU - Cohen, J.

PY - 2014

Y1 - 2014

U2 - 10.1177/1352458514532317

DO - 10.1177/1352458514532317

M3 - Article

C2 - 24812043

SN - 1352-4585

VL - 20

SP - 1704

EP - 1713

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 13

ER -

Barkhof F, Jong R, Sfikas N, de Vera A, Francis G, Cohen J. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis. 2014;20(13):1704-1713. doi: 10.1177/1352458514532317